Age important in hereditary pancreatic cancer risk

NEW YORK (Reuters Health) - For people with a strong family history of pancreatic cancer, having a relative who was diagnosed before the age of 50 may further raise the risk of developing the deadly disease, a new study finds.

In the new study, investigators found that among these families, the age at which affected relatives were diagnosed was an important factor in other family members'' risk of developing the cancer.

Compared with the general population, people in families affected by familial pancreatic cancer had a six-fold higher risk of developing the disease.

But the risk was increased nine-fold when a family member had been diagnosed with the disease before the age of 50, the researchers report in the Journal of the National Cancer Institute.

The findings should help in counseling people at high genetic risk of pancreatic cancer -- giving a clearer picture of an individual''s likelihood of developing the disease, said researcher Dr. Alison P. Klein, of Johns Hopkins School of Medicine in Baltimore.

The results may also help researchers figure out which individuals might benefit most from pancreatic cancer screening to detect suspicious growths early.

Pancreatic cancer has a dismal prognosis, with only about 5 percent of patients still alive five years after diagnosis.

This is largely because the cancer is rarely caught early; its symptoms, which include weight loss, pain in the upper abdomen and jaundice, usually arise only after the cancer has spread.

As it stands, however, people from families affected by hereditary pancreatic cancer are not routinely screened. Researchers are still trying to determine which tests can reliably detect early cancer in people without symptoms, and which individuals within these families are at particular risk.

"Right now, there''s no well-established screening program," Klein told Reuters Health. She and her colleagues at Hopkins are currently studying the effectiveness of endoscopic ultrasound, where an ultrasound probe is passed through the mouth and threaded down into the small intestine, where it is aimed at the pancreas.

The current findings, the researchers say, suggest that clinical trials should focus on families with young-onset pancreatic cancer.